J. Cai

机构：Guangdong Pharmaceutical University · ORCID：0009-0003-8806-9618

发表论文 13 篇 · 总被引 20 次 · h-index 3

代表论文

• 1469MO Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): A multicenter, open-label, randomized phase III trial (2025 · Annals of Oncology · 被引 7)
• Association of cigarette smoking with risk of colorectalcancer subtypes classified by gut microbiota (2023 · Tobacco Induced Diseases · 被引 5)
• 169P Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab (2023 · Annals of Oncology · 被引 3)
• [Value of fecal immunochemical test in colorectal cancer screening]. (2023 · PubMed · 被引 2)
• Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203) (2019 · Annals of Oncology · 被引 2)
• [Research on applying genetic and environmental risk score in risk-adapted colorectal cancer screening]. (2023 · PubMed · 被引 1)